Sputnik V Vaccine Is Delivered to Argentina

December 28, 2020

Sputnik V Vaccine developed by Russian scientists from the Gamaleya National Center of Epidemiology and Microbiology with the support of the Russian Direct Investment Fund (RDIF) has been delivered to Argentina.

The issues related to the transfer of technology for the production of the Sputnik V vaccine abroad and its supply to Argentina have been addressed with the active assistance from the Russian Direct Investment Fund, headed by Kirill Dmitriev, and the Russia-Argentina Business Council, headed by Andrey Guryev.

On the initiative of the RDIF and the Business Council, numerous high-level meetings of representatives of Argentinian and Russian public and private organizations to discuss best practices to counter the spread of coronavirus took place throughout the year.

The possibility of producing the Sputnik V vaccine in Argentina was first discussed during a September meeting of the co-chairs of the Intergovernmental Russian-Argentine Commission of Trade-Economic and Scientific-Technical Cooperation.

“We are grateful to RDIF, Russian members of the Russia-Argentina Business Council, and particularly its Chairman Andrey Guryev for their efforts that have enabled the start of the largest mass vaccination campaign in Argentina’s history.” T

Guryev adds, “This is a great and friendly step that confirms a true strategic partnership between our two countries and strengthens trust and cooperation among Argentinian and Russian business circles. This Christmas Eve, brought us hope in such a difficult context,” said Amalia Sáenz, Chair of the Argentine-Russian Business Council.

“The vaccines against COVID-19 developed in Russia are clearly of great interest internationally. Latin American countries are among those most affected by the pandemic. In this difficult environment, supplying a batch of Sputnik V vaccines to our strategic partner has allowed Argentina to follow Russia, which has already begun a large-scale vaccination program against COVID-19,” Andrey Guryev, Сhair of the Russia-Argentina Business Council, concluded.

“The delivery of the Sputnik V vaccine to Argentina is a truly historic moment and an excellent example of cooperation between our countries. The entire nation watched as the plane carrying the first batch of Sputnik V vaccines landed at Ezeiza Airport on Christmas, giving great hope that this is the beginning of a new era without COVID. The “V” in the name of our vaccine stands for “Victory,” and we wish the people of Argentina a decisive victory over this disease. We support the decision of the Argentine government to include our vaccine in its national portfolio,” commented Kirill Dmitriev, CEO of the Russian Direct Investment Fund.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”